Research Keyword: echinocandin

Prospective Study on Microbiological Profile of Fungal Isolates and its Antibiogram in a Tertiary care hospital in South India

mycolabadmin

Researchers studied fungal infections in a hospital in South India over one year, examining 62 fungal isolates. They found that Candida auris, a dangerous fungal species, was the most common and had developed resistance to many antifungal drugs. A newer class of antifungal drugs called echinocandins worked best against these infections, highlighting the importance of quick identification of fungal species for proper treatment.

Read More »

Efficacy of Rezafungin on Candida albicans Endophthalmitis in a Rabbit Model

mycolabadmin

Researchers tested a new antifungal medication called rezafungin to treat a serious eye infection caused by the fungus Candida albicans. Using rabbit models, they found that rezafungin was much more effective than two other antifungal drugs at clearing the infection from the eye and preventing damage to vision. The drug’s ability to work for longer periods with less frequent dosing makes it a promising candidate for treating this devastating infection in patients.

Read More »

Efficacy of Rezafungin on Candida albicans Endophthalmitis in a Rabbit Model

mycolabadmin

Researchers tested a new antifungal drug called rezafungin against a serious eye infection caused by Candida fungus in rabbits. Rezafungin performed much better than two other commonly used antifungal drugs, completely eliminating the fungus from the eye while preventing infection-related damage. The drug’s ability to be given weekly instead of daily makes it more practical for treating patients with severe fungal eye infections.

Read More »

Revealing structure and shaping priorities in plant and fungal cell wall architecture via solid-state NMR

mycolabadmin

This review explains how scientists use a special type of microscopy called solid-state NMR to study the protective outer layers of fungi and plants. The research shows that fungal pathogens can cleverly rearrange their cell walls to resist antifungal medicines, and that plants carefully organize their cell walls during growth by forming specific connections between different molecules. Understanding these structures at the molecular level could help develop better antifungal treatments and improve how we use plant biomass for biofuels and materials.

Read More »

Candida krusei Empyema: A Lung Transplant Case and Systematic Review of the Literature

mycolabadmin

Candida krusei is a dangerous yeast that causes a serious lung infection called empyema, where pus collects around the lungs. This infection is particularly difficult to treat because the yeast is resistant to common antifungal drugs like fluconazole and can form protective biofilms. This systematic review identified only ten cases of this rare infection in the medical literature, showing how uncommon but serious it is, and found that patients need aggressive treatment with multiple antifungal medications combined with surgical drainage to survive.

Read More »

Clinical Outcomes of Micafungin for Invasive Fungal Infections in the Obese and Nonobese

mycolabadmin

This study examined whether obese patients treated with the antifungal drug micafungin for serious fungal infections had different outcomes compared to non-obese patients. Researchers reviewed 378 patient cases and found that both groups had similar success rates of about 50%, suggesting that the standard dose of micafungin works equally well in obese and non-obese patients. These findings suggest that doctors do not need to prescribe higher doses of micafungin specifically for obese patients, though more research is needed to fully understand how obesity affects antifungal treatment.

Read More »
Scroll to Top